Sugi Predict

Sugi Predict / Compounds / SCHEMBL2551760

SCHEMBL2551760

SCHEMBL2551760

O=C(NCc1ccccc1)c1c[c]ccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 4/20 0.57
▸ HDAC2 Q92769 2/20 0.57
▸ HDAC8 Q9BY41 2/20 0.57
▸ HDAC1 Q13547 2/20 0.55
▸ HPGD P15428 1/20 0.54
▸ TP53 P04637 1/20 0.53
▸ LMNA P02545 1/20 0.53
▸ RAB9A P51151 1/20 0.53
▸ HPGDS O60760 2/20 0.51
▸ APOBEC3A P31941 1/20 0.51
▸ CTDSP1 Q9GZU7 1/20 0.51
▸ APOBEC3G Q9HC16 1/20 0.51
▸ ALDH1A1 P00352 2/20 0.50
▸ ROCK2 O75116 1/20 0.50
▸ RPS6KA5 O75582 1/20 0.50
▸ MAP4K4 O95819 1/20 0.50
▸ PRKCG P05129 1/20 0.50
▸ PRKACA P17612 1/20 0.50
▸ RPS6KB1 P23443 1/20 0.50
▸ MAPK1 P28482 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4018933 0.86 L3MBTL1 (0.56) HDAC6HDAC1HPGDLMNARAB9A
SCHEMBL17594426 0.86 TSHR (0.58) HDAC6HDAC1HPGDLMNARAB9A
SCHEMBL27539868 0.84 HDAC6 (0.57) HDAC6HDAC2HDAC8HDAC1HPGD
SCHEMBL7953890 0.83 HTT (0.59) LMNAALDH1A1MAPK1GAA
SCHEMBL457082 0.82 HDAC6 (0.79) HDAC6HDAC2HDAC8HDAC1HPGD
SCHEMBL4573606 0.81 HDAC6 (0.65) HDAC6HDAC2HDAC8HDAC1HPGD
SCHEMBL1900238 0.81 HDAC6 (0.67) HDAC6HDAC2HDAC8HDAC1HPGD
SCHEMBL8476710 0.81 NPC1 (0.66) HPGDRAB9A
SCHEMBL29184442 0.81 HDAC6 (0.76) HDAC6HDAC2HDAC8HDAC1HPGD
Hydrochloric Acid SCHEMBL3757721 0.81 HDAC6 (0.76) HDAC6HDAC2HDAC8HDAC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3218374-B1 SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN GENENTECH INC (US) 2021-12-29 — — EP claimed
CN-107108614-B Substituted pyrrolopyridines as bromodomain inhibitors 基因泰克公司 2021-06-01 — — CN claimed
US-10150767-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2018-12-11 — — US claimed
US-20170342067-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 — — US claimed
CN-107108614-A It is used as the substituted pyrrolopyridine of Bu Luomo domain inhibitor 基因泰克公司 2017-08-29 — — CN claimed
EP-2552893-B1 ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2014-10-29 — — EP claimed
US-20130096119-A1 Isoquinolin-3-Ylurea Derivatives BUR DANIEL (CH) 2013-04-18 — — US claimed
EP-2552893-A1 ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2013-02-06 — — EP claimed
WO-2011121555-A1 ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2011-10-06 — — WO claimed
EP-3218374-B1 SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN GENENTECH INC (US) 2021-12-29 — — EP disclosed
CN-107108614-B Substituted pyrrolopyridines as bromodomain inhibitors 基因泰克公司 2021-06-01 — — CN disclosed
US-10150767-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2018-12-11 — — US disclosed
CN-108698992-A 2- cyano isoindoline derivatives for treating cancer 特殊治疗有限公司 2018-10-23 — — CN disclosed
US-20170342067-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 — — US disclosed
EP-2552893-A1 ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2013-02-06 — — EP disclosed
WO-2011121555-A1 ANTIBACTERIAL ISOQUINOLIN-3-YLUREA DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2011-10-06 — — WO disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 — — US disclosed
EP-0882730-B1 PHOSPHONIC ACID DIESTER DERIVATIVES OTSUKA PHARMA CO LTD (JP) 2002-10-02 — — EP disclosed
US-5985858-A TREATING AND PREVENTING HYPERLIPIDEMIA, DIABETES AND CATARACT, OR AS AN ANTITUMOR AGENT OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 1999-11-16 — — US disclosed
EP-0882730-A1 PHOSPHONIC ACID DIESTER DERIVATIVES OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 1998-12-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD HDAC6 435/4885HDAC2 1655/4885HDAC8 1737/4885
US-20170342067-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF BRD4, BRDT, BRPF3 HDAC6 20/4885HDAC2 21/4885HDAC8 64/4885
US-10150767-B2 Therapeutic compounds and uses thereof BRD4, BRDT, BRPF3 HDAC6 20/4885HDAC2 21/4885HDAC8 64/4885
US-20130096119-A1 Isoquinolin-3-Ylurea Derivatives CLIC1, IRF3, KCNH3 HDAC6 2674/4885HDAC2 2867/4885HDAC8 4642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.